The North America radiopharmaceutical theranostics market was valued at US$ 795.88 million in 2022 and is expected to reach US$ 1,529.95 million by 2028; it is estimated to register a CAGR of 11.5% from 2022 to 2028.
As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.
Nort
Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.
Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.
Reasons to Buy
Rising Application in Treatment of Cardiovascular Disorders
Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.
North America Radiopharmaceutical Theranostics Market Overview
The North America radiopharmaceutical theranostics market is segmented into US, Canada, and Mexico. The US is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.Nort
h America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)
North America Radiopharmaceutical Theranostics Market Segmentation
The North America radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the North America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.
Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America radiopharmaceutical theranostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America radiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook in regional market coupled with the factors driving the market, as well as those hindering it.
- Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. North America Radiopharmaceutical Theranostics Market - Market Landscape
5. North America Radiopharmaceutical Theranostics Market - Key Market Dynamics
6. Radiopharmaceutical Theranostics Market - North America Analysis
7. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
8. North America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
9. North America Radiopharmaceutical Theranostics Market Analysis - by Source
10. North America Radiopharmaceutical Theranostics Market Analysis - by Application
11. North America Radiopharmaceutical Theranostics Market Analysis - by Indication
12. North America Radiopharmaceutical Theranostics Market Analysis - by End User
13. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis
14. Radiopharmaceutical Theranostics Market - Industry Landscape
15. Company Profiles
16. Appendix
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- GE Healthcare Technologies Inc.
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc.
- Advanced Accelerator Applications S.A
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 185 |
| Published | February 2024 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 795.88 Million |
| Forecasted Market Value ( USD | $ 1529.95 Million |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | North America |
| No. of Companies Mentioned | 10 |
